XBIOTECH INC

XBITNASDAQ

🏆 #3864 by market capUS Equity

$2.35▲ $0.00 (+0.21%)

Live

1h▲ 0.0%

24h▲ 0.2%

7d▲ 3.5%

14d▲ 4.4%

30d▲ 1.3%

1y▼ 21.7%

🏦Market Cap

$72M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $2.34 – $2.38
52-Week Range: $2.09 – $3.61
Volume: $4.60B
Avg Volume: $6.08B
Shares Outstanding: 30.5M
Next Earnings: Oct 21, 2026

Fundamentals Snapshot

Annual Revenue: $36M
Last Q Revenue: $9M
P/E Ratio: -1.8
P/S Ratio: 0.0x
EPS (TTM): $-1.32
Dividend Yield: 0.00%

Why Investors Own XBIT

✓High-growth profile — revenue up +9.1% YoY with expanding US Equity exposure.
✓Healthy economics — 66% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$36M▲ +7.1% YoY

Gross Margin (TTM)

66.1%▲ +4.4% YoY

Operating Income (TTM)

$9M▲ +7.1% YoY

Free Cash Flow (TTM)

$8M▲ +7.1% YoY

About XBIOTECH INC

XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.

🦦